Autopsy report · NCT02928029
Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma
Cause of deathSlow enrollment
“Due to the changes of standard of care and the slow recruitment of participants.”
Life of this trial
- Registered 4 months before it started.
- Ran for about 2 years 1 month before it stopped.
- 7 participants enrolled.
- Results were posted on the registry 11 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Bayer
- Sponsor type
- Industry
- Conditions
- Multiple Myeloma
- Interventions
- Radium-223 dichloride (Xofigo, BAY88-8223); Placebo; Bortezomib; Dexamethasone
- Participants
- 7
- Sites
- 7
- Countries
- South Korea, Spain, United States
Trials that died the same way
- A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC
“Slow enrolment - standard of care evolved over the duration of the study such that treatment regimen employed in the study was no longer current standard of care for first line resulting in recruitment challenges.” - The Risk of Intraventricular Hemorrhage With Flat Midline Versus Right-Tilted Flat Lateral Head Positions
“Due to low patient recruitment” - Evaluation of the Parietex TM Parastomal No Hole Mesh for Repair of Parastomal Hernias in End-colostomies
“too slow patiënts recruitment” - Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
“Lack of enrollment and changing landscape of standard of care.” - Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care
“due to poor patient recruitment”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.